TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Reviva Pharmaceuticals Holdings, Inc.
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Reviva Pharmaceuticals will present research data on brilaroxazine's treatment effects on negative symptoms in schizophrenia patients at the CNS Summit 2025 in Boston, Massachusetts.

Insights
JPMpL   positive

Included in the recommended fund's portfolio as a top performer


RVPH   positive

Company is presenting research data at a prominent medical conference, indicating progress in developing a potential treatment for schizophrenia negative symptoms